Chardan analyst Daniil Gataulin downgraded Outlook Therapeutics (OTLK) to Neutral from Buy without a price target after the company reported preliminary topline efficacy and safety data from the Phase 3 NORSE 8 study of Lytenava in patients with wet age-related macular degeneration. The study did not meet the primary endpoint of non-inferiority compared to ranibizumab, the analyst tells investors in a research note. The firm cites the uncertainty in Lytenava’s regulatory path forward in the U.S. for the downgrade.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OTLK:
- Unusually active option classes on open November 29th
- Outlook Therapeutics price target lowered to $9 from $50 at BTIG
- 3 Penny Stocks to Watch Now, 11/29/24
- Outlook Therapeutics reports preliminary results from Norse Eight trials
- Outlook could disrupt ocular anti-VEGF injection market, says BTIG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
